Biotech
-
Will Sales Growth Save Cronos Group Inc. (NASDAQ: CRON) From selling Pressure?
[ad_1] Will Sales Growth Save Cronos Group Inc. (NASDAQ: CRON) From selling Pressure? Cronos Group Inc. (NASDAQ: CRON) stays below…
Read More » -
From Disease to Looming Food Crisis, Gene Editing Could Unlock Solutions to Our Greatest Problems
[ad_1] Today, celiac illness impacts one in 100 folks worldwide, and with no remedy, the one therapy is a gluten-free…
Read More » -
The Cancer Research Collaboration Partners with Diabetes Prevention Program Provider Blue Mesa Health with California Residents in Mind Nasdaq:RDNT
NEW YORK, Dec. 06, 2018 (GLOBE NEWSWIRE) — The Cancer Research Collaboration (CRC), a non-profit group devoted to increasing the…
Read More » -
BIO Supports Renegotiated U.S. Japan Trade Agreement
[ad_1] BIO helps the U.S. Trade Representative’s (USTR) negotiations with the Government of Japan as a possibility to develop U.S.…
Read More » -
Bellicum reports first data on ‘controllable’ CAR-T
[ad_1] Bellicum Pharma has the first data on BPX-601, its first CAR-T with a built-in activation change to spice up…
Read More » -
-390x220.jpg)
Sensorion’s vertigo drug hits tolerability endpoint in phase 2
[ad_1] A phase 2a trial of Sensorion’s vertigo seliforant has met its major tolerability endpoint. The trial discovered the histamine…
Read More » -
-390x220.jpg)
Axovant buys more gene therapies, setting it up for a busy 2019
[ad_1] Axovant has licensed two gene therapies from the University of Massachusetts Medical School (UMMS). The deal accelerates Axovant’s evolution…
Read More » -
Extendicare Announces December 2018 Dividend of C$0.04 per Share Toronto Stock Exchange:EXE
[ad_1] MARKHAM, Ontario, Dec. 13, 2018 (GLOBE NEWSWIRE) — Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) introduced that it…
Read More » -
CRISPR controls obesity in mice by amplifying rather than editing genes
[ad_1] The genes SIM1 and MC4R regulate food consumption by signaling the sensation of being full, which is why mutations…
Read More » -
Sunovion, PsychoGenics nondopamine schizophrenia drug meets phase 2 endpoint
[ad_1] Sunovion Pharmaceuticals and PsychoGenics unveiled constructive phase 2 outcomes for a brand new schizophrenia therapy that doesn’t bind to…
Read More »
